A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin

Journal of the Formosan Medical Association

Volumn 113, Issue 10, 2014, Pages 716-721

  Hsu, Ching Sheng ^a,b   Hsu, Shih Jer ^c,d   Lin, Hans Hsienhong ^a,b   Tseng, Tai Chung ^a,b   Wang, Chia Chi ^a,b   Chen, Ding Shinn ^c,d,e   Kao, Jia Horng ^c,d  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Hepatitis C virus; Insulin resistance; Oral hypoglycemic agents; Pegylated interferon; Randomized controlled trial; Sustained virological response

Indexed keywords

ACARBOSE; METFORMIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERFERON; ANTIDIABETIC AGENT; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTHYROIDISM; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PANCYTOPENIA; PILOT STUDY; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; TAIWAN; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO; VIRAL CLEARANCE; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MULTIDRUG RESISTANCE; PROCEDURES; SEX DIFFERENCE; VIROLOGY; VIRUS LOAD;

ACARBOSE; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SEX FACTORS; THIAZOLIDINEDIONES; VIRAL LOAD;

EID: 84922622860     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2014.05.007     Document Type: Article

References (26)

1. Williams R. Global challenges in liver disease. Hepatology 2006, 44:521-526.
2. Ryoo S.M., Kim W.Y., Kim W., Lim K.S., Lee C.C., Woo J.H. Transmission of hepatitis C virus by occupational percutaneous injuries in South Korea. J Formos Med Assoc 2012, 111:113-117.
3. Tseng Y.T., Sun H.Y., Chang S.Y., Wu C.H., Liu W.C., Wu P.Y., et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan. J Formos Med Assoc 2012, 111:431-438.
4. Strader D.B., Wright T., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
5. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-S244.
6. Yang W.L., Lee J.Y. Extensive inflammation of actinic keratoses during interferon α therapy for chronic hepatitis C in a Taiwanese albino woman. J Formos Med Assoc 2013, 112:728-729.
7. Li Q., Péne V., Krishnamurthy S., Cha H., Liang T.J. Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med 2013, 19:722-729.
8. Hsu C.S., Kao J.H. Hepatitis C infection and metabolic syndrome. J Formos Med Assoc 2010, 109:403-407.
9. Hsu C.S., Kao J.H. Fluvastatin helps interferon-based therapy in chronic hepatitis C: fact or fiction?. J Gastroenterol Hepatol 2013, 28:7-9.
10. Hsu C.S., Kao J.H. Genomic variation-guided management in chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2012, 6:497-506.
11. Kawaguchi T., Ide T., Taniguchi E., Hirano E., Itou M., Sumie S., et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007, 102:570-576.
12. Hsu C.S., Liu C.H., Liu C.J., Hsu S.J., Chen C.L., Hwang J.J., et al. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J Gastroenterol Hepatol 2010, 25:970-977.
13. Conjeevaram H.S., Wahed A.S., Afdhal N., Howell C.D., Everhart J.E., Hoofnagle J.H., et al. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011, 140:469-477.
14. Romero-Gómez M., Diago M., Andrade R.J., Calleja J.L., Salmerón J., Fernández-Rodríguez C.M., et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50:1702-1708.
15. Lee S.D., Yu M.L., Cheng P.N., Lai M.Y., Chao Y.C., Hwang S.J., et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005, 12:283-291.
16. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004, 328:983.
17. Prati D., Shiffman M.L., Diago M., Gane E., Rajender Reddy K., et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 2006, 44:679-685.
18. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
19. Hsu C.S., Liu C.J., Liu C.H., Wang C.C., Chen C.L., Lai M.Y., et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008, 28:271-277.
20. Hsu C.S., Liu C.H., Liu C.J., Chen C.L., Lai M.Y., Chen P.J., et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009, 14:45-54.
21. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
22. Dai C.Y., Huang J.F., Hsieh M.Y., Hou N.J., Lin Z.Y., Chen S.C., et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009, 50:712-718.
23. Khattab M., Emad M., Abdelaleem A., Eslam M., Atef R., Shaker Y., et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010, 30:447-454.
24. Hsu C.S., Hsu S.J., Chen H.C., Tseng T.C., Liu C.H., Niu W.F., et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A 2011, 108:3719-3724.
25. Hsu C.S., Kao J.H. Boceprevir for chronic HCV genotype 1 infection. N Engl J Med 2011, 365:176-177.
26. Hsu C.S., Kao J.H., Chao Y.C., Lin H.H., Fan Y.C., Huang C.J., et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013, 38:415-423.